NRXS
BEARISH
$7.45
Live
NeurAxis, Inc. · AMEX
Target $11.0
(+47.7%)
$1.94
52W Range
$8.4
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated May 01, 2026
Market cap
$85.72M
P/E
N/A
ROE
-285.4%
Profit margin
-218.5%
Debt/Equity
0.13
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
90%
NRXS exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of financial health metrics. While the stock has seen a speculative 217% price increase over the last year, this is completely disconnected from its fundamentals, as evidenced by a -218.55% profit margin and an extreme Price-to-Book ratio of 23.35. Despite moderate revenue growth and a strong current ratio, the company is destroying equity at an alarming rate (ROE -285.36%). The current valuation is unsustainable without a massive and immediate pivot to profitability.
Key Strengths
Strong Gross Margin (84.23%) suggesting high product value
Healthy liquidity with a Current Ratio of 2.05
Low Debt/Equity ratio (0.13) reducing immediate insolvency risk
Positive YoY Revenue Growth of 27.20%
Recent improvement in EPS growth (+68.8% YoY)
Key Risks
Extreme operational losses (Profit Margin -218.55%)
Severe fundamental weakness (Piotroski F-Score 1/9)
Extreme valuation premiums (P/S 24.01, P/B 23.35)
Poor earnings track record with only 1 of the last 4 quarters beating estimates
High dependence on speculative sentiment given the bearish technical trend (10/100)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
20
Weak
10
45
30
15
0
AI Verdict
Speculative Bubble
Key drivers: Piotroski F-Score 1/9, Extreme P/B and P/S ratios, Massive negative profit margins, Disconnect between price action and fundamentals
Confidence
95%
Value
10/100
Graham Number is N/A due to lack of positive earnings; stock trades at a massive premium.
Positives
No standout positives identified.
Watchpoints
- P/B of 23.35 is excessive
- P/S of 24.01 is unsustainable for this growth rate
- Forward P/E is deeply negative
Future
45/100
Growth is present but insufficient to justify current valuation.
Positives
- Revenue growth is consistent
- EPS is trending upward from deep lows
Watchpoints
- Burn rate remains high
- Path to profitability is not yet evident in margins
Past
30/100
Price performance is driven by momentum/speculation rather than earnings.
Positives
- Exceptional 1-year price performance (+217%)
Watchpoints
- Consistent earnings misses (3/4 last quarters)
- Historical ROE is deeply negative
Health
15/100
Altman Z-Score not provided, but F-Score suggests high operational distress.
Positives
- Low debt levels
- Adequate current ratio
Watchpoints
- Piotroski F-Score 1/9 indicates critical weakness
- Negative ROA and ROE
Dividend
0/100
Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No capacity for dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$7.45
Analyst Target
$11.0
Upside/Downside
+47.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NRXS and closest competitors.
Updated 2026-04-30
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NRXS
NeurAxis, Inc.
Primary
|
+24.2% | +24.2% | +217.0% | +167.0% | +0.7% | 0.0% |
|
TCRX
TScan Therapeutics, Inc.
Peer
|
-86.4% | -42.1% | -6.5% | -43.2% | +37.5% | +40.2% |
|
OKYO
OKYO Pharma Limited
Peer
|
-54.4% | +32.0% | +47.3% | -20.3% | -1.8% | +3.8% |
|
GOSS
Gossamer Bio, Inc.
Peer
|
-95.6% | -66.2% | -57.8% | -85.5% | -26.7% | +0.4% |
|
QTI
QT Imaging Holdings, Inc.
Peer
|
-95.3% | -95.6% | -34.0% | -78.7% | +0.9% | +0.3% |
NRX
NeurAxis, Inc.
Primary
5Y
+24.2%
3Y
+24.2%
1Y
+217.0%
6M
+167.0%
1M
+0.7%
1W
0.0%
TCR
TScan Therapeutics, Inc.
Peer
5Y
-86.4%
3Y
-42.1%
1Y
-6.5%
6M
-43.2%
1M
+37.5%
1W
+40.2%
OKY
OKYO Pharma Limited
Peer
5Y
-54.4%
3Y
+32.0%
1Y
+47.3%
6M
-20.3%
1M
-1.8%
1W
+3.8%
GOS
Gossamer Bio, Inc.
Peer
5Y
-95.6%
3Y
-66.2%
1Y
-57.8%
6M
-85.5%
1M
-26.7%
1W
+0.4%
QTI
QT Imaging Holdings, Inc.
Peer
5Y
-95.3%
3Y
-95.6%
1Y
-34.0%
6M
-78.7%
1M
+0.9%
1W
+0.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-248.33
PEG Ratio
N/A
P/B Ratio
23.35
P/S Ratio
24.01
EV/Revenue
22.08
EV/EBITDA
-11.04
Market Cap
$85.72M
Profitability
Profit margins and return metrics
Profit Margin
-218.55%
Operating Margin
-177.34%
Gross Margin
84.23%
ROE
-285.36%
ROA
-80.63%
Growth
Revenue and earnings growth rates
Revenue Growth
+27.2%
Earnings Growth
N/A
Q/Q Revenue Growth
+27.19%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.13
Low debt
Current Ratio
2.05
Strong
Quick Ratio
1.85
Excellent
Cash/Share
$0.44
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
85.4%
Op. Margin
-177.3%
Net Margin
-176.5%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.88x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
105%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-19
$-0.1
+54.0% surprise
2025-11-10
$-0.24
-20.0% surprise
2025-08-12
$-0.22
-15.8% surprise
2025-05-12
$-0.33
-37.5% surprise
Healthcare Sector Comparison
Comparing NRXS against 582 companies in the Healthcare sector
(37 bullish, 181 neutral, 364 bearish)
Return on Equity (ROE)
-285.36%
This Stock
vs
-87.12%
Sector Avg
+227.6%
(Excellent)
Profit Margin
-218.55%
This Stock
vs
-16.02%
Sector Avg
+1264.6%
(Superior)
Debt to Equity
0.13
This Stock
vs
2.6
Sector Avg
-95.2%
(Less Debt)
Revenue Growth
27.2%
This Stock
vs
120.93%
Sector Avg
-77.5%
(Slower)
Current Ratio
2.05
This Stock
vs
4.39
Sector Avg
-53.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NRXS
NeurAxis, Inc.
|
BEARISH | $85.72M | - | -285.4% | -218.5% | $7.45 | |
|
TCRX
TScan Therapeutics, Inc.
|
BEARISH | $85.94M | - | -71.3% | -% | $1.43 | Compare |
|
OKYO
OKYO Pharma Limited
|
BEARISH | $86.59M | - | -% | -% | $1.65 | Compare |
|
GOSS
Gossamer Bio, Inc.
|
BEARISH | $87.21M | - | -% | -% | $0.37 | Compare |
|
QTI
QT Imaging Holdings, Inc.
|
BEARISH | $83.45M | - | -% | -111.4% | $6.93 | Compare |
NRXS
NeurAxis, Inc.
BEARISH
Mkt Cap
$86M
P/E
-
ROE
-285.4%
Price
$7.45
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | CARRICO THOMAS JOESEPH | Officer | Purchase | 667 | $4,789 |
| 2026-04-01 | CARRICO BRIAN ALLEN | Chief Executive Officer | Purchase | 8,060 | $57,871 |
| 2026-04-01 | HENRICHS TIMOTHY ROBERT | Chief Financial Officer | Purchase | 7,593 | $54,518 |
| 2026-02-12 | HANNASCH BRIAN | Beneficial Owner of more than 10% of a Class of Security | Purchase | 80,000 | $382,800 |
| 2026-01-22 | FERGE KRISTIN A | Director | Stock Award | 21,598 | $99,999 |
| 2026-01-22 | AHARON GILAD S. | Director | Stock Award | 21,598 | $99,999 |
| 2026-01-22 | WATKINS BRADLEY MITCHELL | Director | Stock Award | 21,598 | $99,999 |
| 2026-01-22 | KEYSER JANE ELIZABETH | Director | Stock Award | 21,598 | $99,999 |
| 2025-12-23 | AHARON GILAD S. | Director | Purchase | 286,138 | $1,007,206 |
CARRICO THOMAS JOESEPH
Officer
2026-04-01
667 shares
·
$4,789
CARRICO BRIAN ALLEN
Chief Executive Officer
2026-04-01
8,060 shares
·
$57,871
HENRICHS TIMOTHY ROBERT
Chief Financial Officer
2026-04-01
7,593 shares
·
$54,518
HANNASCH BRIAN
Beneficial Owner of more than 10% of a Class of Security
2026-02-12
80,000 shares
·
$382,800
FERGE KRISTIN A
Director
2026-01-22
21,598 shares
·
$99,999
AHARON GILAD S.
Director
2026-01-22
21,598 shares
·
$99,999
WATKINS BRADLEY MITCHELL
Director
2026-01-22
21,598 shares
·
$99,999
KEYSER JANE ELIZABETH
Director
2026-01-22
21,598 shares
·
$99,999
AHARON GILAD S.
Director
2025-12-23
286,138 shares
·
$1,007,206
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
8-K
8-K
10-K
10-Q
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
2 analysts
Craig-Hallum
2026-03-20
Buy
Buy
Craig-Hallum
2025-12-22
Buy
Buy
Past News Coverage
Recent headlines mentioning NRXS from our newsroom.
Newest → oldest
No matching news yet.